2006 Interactive Annual Report: Building Vertex
Joshua Boger, Ph.D.
President & Chief Executive Officer“ We made substantial progress across our business in 2006 and are today an exciting, fast-growing company with the opportunity to change the treatment of serious diseases. We are honored to be part of the Nasdaq-100 Index, a significant recognition of our progress over recent years. We expect to build on momentum generated in 2006 as we move forward to build Vertex on telaprevir.”
Kelly Blackburn
Vice President
Clinical Development Operations“ In 2007, Vertex expects to run global clinical trials for several of our development programs, including the largest Phase 2 clinical program ever run in hepatitis C. Later this year, we expect to initiate the Phase 3 program for telaprevir – an important milestone and an operational challenge as well. We have enhanced our cross-functional capabilities in managing global clinical programs and are committed to advancing our pipeline as the Company grows throughout 2007.”
Craig Millian
Vice President
Customers and Markets“ As medical innovations emerge, no longer can we rely on past assumptions about the treatment of disease. This is especially true in hepatitis C. At Vertex, we are developing a deeper knowledge of how this disease impacts patients’ lives, as well as the true burden of HCV on society and the health care system. By understanding the unique challenges for patients living with HCV, we will best be able to serve their needs as we bring telaprevir forward in development.”
Lisa Kelly
Vice President
Human Resources“ As the Company grows, we are creating what we call ‘The Vertex Experience.’ It’s not only what you do here, but how you do it that will provide for interesting and varied career development. At Vertex, a free and respectful exchange of ideas supports each employee’s pursuit of our core purpose. It’s beyond the traditional open door policy.
We believe that ‘The Vertex Experience’ should be so strong that both Vertex employees and alumni will encourage others to consider joining us. We invite you to be a part of it.”
Mark Namchuk, Ph.D.
Vice President
Research, Cambridge“ It often takes years of research and thousands of experiments to find a compound with the potential to treat a disease in a new way. We are not looking for just one such opportunity; we want to succeed repeatedly and bring forward multiple transformational compounds. The end result may be a dramatic improvement to a person’s health and a fundamental change in medicine. This is an inspiring outcome that makes our work incredibly rewarding.”
